Denali Therapeutics (DNLI) Change in Cash (2017 - 2026)

Denali Therapeutics (DNLI) has reported Change in Cash for 10 consecutive years, with $182.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 256.5% year-over-year to $182.3 million; the TTM figure through Mar 2026 stood at $330.7 million (up 15876.67% YoY), while the FY2025 annual figure was $31.9 million, down 33.35% from the prior year.
• Change in Cash advanced to $182.3 million in Q1 2026 per DNLI's latest filing, from $114.4 million in the prior quarter.
• Across five years, Change in Cash topped out at $182.3 million in Q1 2026 and bottomed at -$188.5 million in Q1 2022.
• Historically, Change in Cash has averaged $5.6 million across 5 years, with a median of $16.0 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Cash surged 503.37% — and 2025, when it plunged 414.87%.
• Denali Therapeutics' Change in Cash stood at $99.4 million in 2022, then sank by 121.03% to -$20.9 million in 2023, then soared by 503.37% to $84.3 million in 2024, then surged by 35.62% to $114.4 million in 2025, then jumped by 59.4% to $182.3 million in 2026.
• Business Quant data shows DNLI's Change in Cash at $182.3 million in Q1 2026, $114.4 million in Q4 2025, and -$50.2 million in Q3 2025.